Skip to content
AIM ImmunoTech Inc. Logo AIM ImmunoTech Inc. Logo
  • COMPANY
  • PRODUCTS
  • R & D
    • Product Candidates Overview
    • Pipeline
    • Orphan Drug Designations
  • PARTNERING
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • XBRL Filings
    • Stockholder Meeting
    • Corporate Governance
    • Email Alerts
    • Investor Contact
  • BLOG
  • CONTACT

XBRL Filings

XBRL FilingsAIM ImmunoTech2019-02-28T21:10:58-04:00

Latest News

  • AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19
  • AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers

Privacy / Terms of Use

  • Terms Of Use
  • Investor Contact

Tweets by AIM Immuno

© Copyright    |    All Rights Reserved   |   AIM ImmunoTech Inc.   |   Privacy Policy   |   Terms of Use
facebooktwitteryoutubelinkedin